Zobrazeno 1 - 10
of 30
pro vyhledávání: '"William M. Siders"'
Autor:
William M. Siders, Qingping Wang, Rui Kuai, Jonathan Rothblatt, Francisco J. Quintana, Juliet Musabeyezu, Yuka Milton, Heidi Kuang, Manal Alaamery, Ivan D. Mascanfroni, Martina Heinelt, Veit Rothhammer, Ali H. Alhasan, Haoyue Lan, Jessica E. Kenison, Marie-Christine Multon, Jeffrey M. Karp, Helia Safaee, Christelle Perrault, Oren Levy, Michael De Biasio, Tahir Majid, Salam Massadeh, Ada Yeste, Zhixiang Tong
Publikováno v:
J Mol Med (Berl)
Mesenchymal stem cells (MSCs) are promising candidates for the development of cell-based drug delivery systems for autoimmune inflammatory diseases, such as multiple sclerosis (MS). Here, we investigated the effect of Ro-31-8425, an ATP-competitive k
Autor:
Johanne Kaplan, Jamie Dempsey Barber, Robert L. Treuting, William M. Siders, Yuhan Zhu, Debashree Chakrabarti, Mahta Samizadeh
Publikováno v:
Cancer Research. 79:299-299
Depending upon the definition used, as many as half of all cancers diagnosed are considered rare cancers, and most rare cancer patients would greatly benefit from additional therapies. Repurposing of drugs for use in oncology represents an attractive
Autor:
Johanne Kaplan, William M. Siders, Evis Havari, Tri-Hung Nguyen, Michael J. Turner, Srinivas Shankara, Bruce L. Roberts, Juanita Campos-Rivera
Publikováno v:
Immunology. 141:123-131
Alemtuzumab is a humanized monoclonal antibody specific for the CD52 protein present at high levels on the surface of B and T lymphocytes. In clinical trials, alemtuzumab has shown a clinical benefit superior to that of interferon-β in relapsing-rem
Autor:
William M. Siders, Tri-Hung Nguyen, Jacqueline Shields, Matthew Gale, Yanping Hu, Mark Swistak, Carrie Garron, Gary Jacques, Johanne Kaplan, Robert Fogle
Publikováno v:
Leukemia & Lymphoma. 53:130-138
The interaction between CXCR4 on the surface of tumor cells and CXCL12 in the stroma is believed to contribute to tumor cell survival and protection against drug treatment. Inhibition of stromal survival signals by CXCR4 antagonists has been reported
Autor:
Johanne Kaplan, Jon Goetz, Rodrigo Bravo, Katherine Arline, Christopher Higginson, Jamie Dempsey Barber, Robert L. Treuting, Emily Zeme, William M. Siders
Publikováno v:
Cancer Research. 78:1198-1198
Rare cancers are an understudied and deadly public health problem. Estimates for the percentage of cancer diagnoses that are rare vary depending upon the source cited and the definition of what constitutes a rare cancer. A frequently cited report sta
Publikováno v:
Cancer Research. 78:4801-4801
Adenoid Cystic Carcinoma (ACC) is a rare adenocarcinoma arising most commonly in the major and minor salivary glands of the head and neck. Despite a deepening understanding of the molecular events that lead to sustained tumor growth, there are curren
Autor:
William M. Siders, Srinivas Shankara, Jacqueline Shields, Paula Boutin, Carrie Garron, Johanne Kaplan, Yanping Hu, William Weber, Bruce L. Roberts
Publikováno v:
Leukemia & Lymphoma. 51:1293-1304
Alemtuzumab is a recombinant humanized IgG1 monoclonal antibody directed against CD52, an antigen expressed on the surface of normal and malignant B and T lymphocytes. Alemtuzumab is approved for the treatment of B-cell chronic lymphocytic leukemia (
Publikováno v:
Clinical and Translational Science. 2:75-79
Immunization with the electrofusion product of tumor cells and dendritic cells (DCs) is a promising approach to cancer immunotherapy. Production of electrofusion vaccines currently requires the acquisition of tumor material and must be tailored to ea
Autor:
William M. Siders, Johanne Kaplan, Abraham Scaria, Michael Lukason, Jacqueline Shields, Sam Wadsworth, Lisa Woodworth
Publikováno v:
Human Gene Therapy. 20:11-20
The use of adeno-associated viral (AAV) vectors for gene replacement therapy is currently being explored in several clinical indications. However, reports have suggested that input capsid proteins from AAV-2 vector particles may result in the stimula
Publikováno v:
Molecular Therapy. 6:519-527
We have demonstrated recently that treatment of established peritoneal mesothelial tumors with complexes composed of cationic lipid and noncoding plasmid DNA (pNull) results in the inhibition of tumor growth accompanied by the induction of a tumor-sp